Ara-290 Dosage Protocol | PeptideDosages.com

If you miss 5 or more consecutive days during the first two weeks of a protocol, consider restarting the inflammatory-phase dosing schedule rather than picking up where you left off. ARA-290's benefit during acute injury is tied to modulating the initial cytokine surge. Missing that window means you're dosing into a later repair phase where lower doses or discontinuation may be more appropriate. If the gap occurs after week 3, simply resume at the scheduled dose and extend the protocol duration by the number of missed doses to maintain cumulative exposure.

Administer the missed dose as soon as you remember if fewer than 48 hours have passed since the scheduled time, then resume your regular three-times-weekly schedule from that point forward. ARA-290's 4–5 hour half-life means plasma concentrations drop below the IRR activation threshold within 16 hours, so a 36-hour gap creates a brief trough in neuroprotective signaling but doesn't reset your progress. Missing doses frequently (more than once per four-week cycle) reduces cumulative receptor activation time and may compromise nerve fiber regeneration outcomes, as the tissue-protective gene expression triggered by IRR signaling requires sustained exposure over weeks to produce measurable structural changes.

Extend the protocol to 8–12 weeks before concluding non-response. Neuropathic pain scores in published trials showed continued improvement through week 12, with some patients experiencing delayed response after week 4. The IRR pathway promotes nerve regeneration at 1mm per day. Functional recovery lags behind initial anti-nociceptive effects. If no improvement occurs by week 8, consider that ARA-290 targets small fiber neuropathy specifically, not large fiber involvement or granulomatous compression, which may require different intervention.

Two possibilities: the inflammatory stimulus is ongoing (infection not cleared, autoimmune process still active), or the dose is subtherapeutic for the specific inflammatory load. ARA-290 modulates the inflammatory response but does not eliminate the underlying cause. If the inciting trigger persists, cytokine levels will remain elevated despite peptide administration. Extend the protocol to 10–14 days at the current dose before escalating to 8mg, and verify that baseline inflammatory markers were elevated at protocol initiation. Some chronic inflammatory states require 3–4 weeks of dosing before measurable biomarker changes appear.

Administer the missed dose as soon as you remember if fewer than 48 hours have passed, then resume the regular tri-weekly schedule. If more than 48 hours have elapsed, skip that dose and continue with the next scheduled injection. Do not double-dose to compensate. ARA-290's mechanism relies on sustained IRR activation across the week, so missing a single dose creates a gap in receptor occupancy but doesn't negate prior doses. Missing more than two consecutive doses in a 4-week protocol reduces efficacy measurably, as seen in protocol adherence subgroup analyses from the sarcoidosis trial where <80% adherence correlated with diminished CNFD improvement.